Christian Daugaard Peters

Dr. Christian Daugaard Peters

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Journal Of Hypertension
Verified
Journal Article
Open access
OMOle N. Mathiassen
Ole N. Mathiassen
HVHenrik Vase
Henrik Vase
JBJesper Nørgaard Bech
Jesper Nørgaard Bech
KCKent L. Christensen
Kent L. Christensen
NBNiels Henrik Buus
Niels Henrik Buus
AKAnne Kaltoft
Anne Kaltoft
Renal denervation (RDN), treating resistant hypertension, has, in open trial design, been shown to lower blood pressure (BP) dramatically, but this was primarily with respect to office BP. We conducted a SHAM-controlled, double-blind, randomized, single-center trial to establish efficacy data based on 24-h ambulatory BP measurements (ABPM). Inclusion criteria were daytime systolic ABPM at least 145 mmHg following 1 month of stable medication and 2 weeks of compliance registration. All RDN procedures were carried out by an experienced operator using the unipolar Medtronic Flex catheter (Medtronic, Santa Rosa, California, USA). We randomized 69 patients with treatment-resistant hypertension to RDN (n = 36) or SHAM (n = 33). Groups were well balanced at baseline. Mean baseline daytime systolic ABPM was 159 ± 12 mmHg (RDN) and 159 ± 14 mmHg (SHAM). Groups had similar reductions in daytime systolic ABPM compared with baseline at 3 months [-6.2 ± 18.8 mmHg (RDN) vs. -6.0 ± 13.5 mmHg (SHAM)] and at 6 months [-6.1 ± 18.9 mmHg (RDN) vs. -4.3 ± 15.1 mmHg (SHAM)]. Mean usage of antihypertensive medication (daily defined doses) at 3 months was equal [6.8 ± 2.7 (RDN) vs. 7.0 ± 2.5 (SHAM)].RDN performed at a single center and by a high-volume operator reduced ABPM to the same level as SHAM treatment and thus confirms the result of the HTN3 trial. Further, clinical use of RDN for treatment of resistant hypertension should await positive results from double-blinded, SHAM-controlled trials with multipolar ablation catheters or novel denervation techniques.

17 May 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
ELEsben Laugesen
Esben Laugesen
KOKevin K. W. Olesen
Kevin K. W. Olesen
CPChristian Daugaard Peters
Christian Daugaard Peters
NBNiels Henrik Buus
Niels Henrik Buus
MMMichael Maeng
Michael Maeng
PPPer L. Poulsen
Per L. Poulsen
Background: Estimated pulse wave velocity (ePWV) calculated by equations using age and blood pressure has been suggested as a new marker of mortality and cardiovascular risk. However, the prognostic potential of ePWV during long‐term follow‐up in patients with symptoms of stable angina remains unknown. Methods and Results: In this study, ePWV was calculated in 25 066 patients without diabetes, previous myocardial infarction (MI), stroke, heart failure, or valvular disease (mean age 63.7±10.5 years, 58% male) with stable angina pectoris undergoing elective coronary angiography during 2003 to 2016. Multivariable Cox models were used to assess the association with incident all‐cause mortality, MI, and stroke. Discrimination was assessed using Harrell´s C‐index. During a median follow‐up period of 8.5 years (interquartile range 5.5–11.3 years), 779 strokes, 1233 MIs, and 4112 deaths were recorded. ePWV was associated with all‐cause mortality (hazard ratio [HR] per 1 m/s, 1.13; 95% CI, 1.05–1.21) and MI (HR per 1 m/s 1.23, 95% CI, 1.09–1.39) after adjusting for age, systolic blood pressure, body mass index, smoking, estimated glomerular filtration rate, Charlson Comorbidity Index score, antihypertensive treatment, statins, aspirin, and number of diseased coronary arteries. Compared with traditional risk factors, the adjusted model with ePWV was associated with a minor but likely not clinically relevant increase in discrimination for mortality, 76.63% with ePWV versus 76.56% without ePWV, P <0.05. Conclusions: In patients with stable angina pectoris, ePWV was associated with all‐cause mortality and MI beyond traditional risk factors. However, the added prediction of mortality was not improved to a clinically relevant extent.

29 November 2008 in European Journal of Heart Failure
Verified
Journal Article
Closed access
AAAsger Andersen
Asger Andersen
JNJan Møller Nielsen
Jan Møller Nielsen
CPChristian Daugaard Peters
Christian Daugaard Peters
USUffe Kjær Schou
Uffe Kjær Schou
ESErik Sloth
Erik Sloth
JNJens Erik Nielsen-Kudsk
Jens Erik Nielsen-Kudsk
Background: Sustained pressure overload of the right ventricle (RV) causes RV hypertrophy and failure. Cyclic-GMP has previously been shown to modulate left ventricular hypertrophy. Aim: To evaluate the effects of sildenafil, a phosphodiesterase-5 (PDE5) inhibitor elevating c-GMP, on myocardial hypertrophy and function in rats with RV hypertrophy. Methods: Rats were pulmonary trunk banded (PTB) and randomized to receive sildenafil (SIL) or vehicle (VEC) for three (n = 14) and nine weeks (n = 18). In addition, rats with established RV hypertrophy were randomized to SIL or VEC (n = 17) three weeks after PTB. Right ventricular function was evaluated by echocardiography and RV hypertrophy by histology and RV weight. Results: Sildenafil failed to inhibit the development of RV hypertrophy when given for both 3 and 9 weeks. On the contrary, sildenafil increased RV hypertrophy after 3 weeks (RV/bodyweight: SIL 0.099±0.016 vs. VEC 0.081±0.011; p<0.05) and total heart weight after 9 weeks (SIL 1.05±0.10 vs. VEC 0.93±0.08g; p<0.05). Sildenafil also failed to reverse established RV hypertrophy, but significantly improved RV myocardial function as measured by Tricuspid Annular Plane Systolic Excursion (TAPSE: SIL 1.8±0.027 vs. VEC 1.39±0.037 mm; p<0.05). Conclusion: PDE5 inhibition by sildenafil failed to prevent or reverse RV hypertrophy in rats operated by pulmonary trunk banding. It actually increased RV hypertrophy and improved RV contractile function when given to rats with established RV hypertrophy.

1 September 2014 in Kidney International
Verified
Journal Article
Closed access
CPChristian Daugaard Peters
Christian Daugaard Peters
KKKrista D. Kjaergaard
Krista D. Kjaergaard
JJJens D. Jensen
Jens D. Jensen
KCKent L. Christensen
Kent L. Christensen
CSCharlotte Strandhave
Charlotte Strandhave
BJBente Jespersen
Bente Jespersen

1 November 2005 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
SKSoo Wan Kim
Soo Wan Kim
USUffe K. Schou
Uffe K. Schou
CPChristian Daugaard Peters
Christian Daugaard Peters
SSSophie de Seigneux
Sophie de Seigneux
TKTae-Hwan Kwon
Tae-Hwan Kwon
SNSøren Nielsen
Søren Nielsen
It was hypothesized that dysregulation of renal epithelial sodium channel (ENaC) subunits and/or 11β-hydroxysteroid dehydrogenase (11βHSD2) may play a role in the increased sodium retention in liver cirrhosis (LC). Experimental LC was induced in rats by CCl4 (1 ml/kg, intraperitoneally, twice a week) for 12 wk (protocol 1) or for 11 wk (protocol 2). In both protocols, one group of rats with cirrhosis showed significantly decreased urinary sodium excretion and urinary Na/K ratio (group A), whereas a second group exhibited normal urinary sodium excretion (group B) compared with controls, even though extensive ascites was seen in both groups of rats with cirrhosis. In group A, protein abundance of α-ENaC was unchanged, whereas β-ENaC abundance was decreased in the cortex/outer stripe of outer medulla compared with controls. The γ-ENaC underwent a complex change associated with increased abundance of the 70-kD band with a concomitant decrease in the main 85-kD band, corresponding to an aldosterone effect. In contrast, no changes in the abundance of ENaC subunit were observed in group B. Immunoperoxidase microscopy revealed an increased apical targeting of α-, β-, and γ-ENaC subunits in distal convoluted tubule (DCT2), connecting tubule (CNT), and cortical and medullary collecting duct segments in group A but not in group B. Immunolabeling intensity of 11βHSD2 in the DCT2, CNT, and cortical collecting duct was significantly reduced in group A but not in group B, and this was confirmed by immunoblotting. In conclusion, increased apical targeting of ENaC subunits combined with diminished abundance of 11βHSD2 in the DCT2, CNT, and cortical collecting duct is likely to play a role in the sodium retaining stage of liver cirrhosis.

4 December 2013 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
ELEsben Laugesen
Esben Laugesen
NRNiklas B. Rossen
Niklas B. Rossen
CPChristian Daugaard Peters
Christian Daugaard Peters
MMMichael Mæng
Michael Mæng
EEEva Ebbehøj
Eva Ebbehøj
PPPer Løgstrup Poulsen
Per Løgstrup Poulsen
The SphygmoCor is used for noninvasive assessment of ascending aortic blood pressure (BP). However, the validity of the SphygmoCor transfer function has not been tested in an exclusively type 2 diabetic patient sample. Calibration with systolic (SBP) and diastolic (DBP) brachial BP has previously been associated with substantial imprecision of central BP estimates. We hypothesized that different noninvasive calibration strategies might improve the accuracy of the estimated ascending aortic BPs. In 34 patients with type 2 diabetes we estimated ascending aortic SBP and DBP using the SphygmoCor device and compared these data with invasively recorded data. The validity of the transfer function was assessed by calibrating with invasively recorded DBP and mean BP (MBP). The influence of noninvasive calibration strategies was assessed by calibrating with brachial oscillometric SBP+DBP vs. DBP+MBP using a form factor (ff) of 0.33 and 0.40, respectively. When calibrating with invasive BP, the difference between estimated and invasively measured ascending aortic SBP and DBP was −2.3±5.6/1.0±0.9mm Hg. When calibrating with oscillometric brachial BPs, the differences were −9.6±8.1/14.1±6.2mm Hg (calibration with SBP and DBP), −8.3±11.7/13.9±6.1mm Hg (DBP and MBP; ff = 0.33), and 1.9±12.2/14.1±6.2mm Hg (DBP and MBP; ff = 0.40), respectively. Calibration with the average of 3 brachial BPs did not improve accuracy. The SphygmoCor transfer function seems valid in patients with type 2 diabetes. Noninvasive calibration with DBP and MBP (ff = 0.40) enables accurate estimation of mean ascending aortic SBP at the group level. However, the wide limits of agreement indicate limited accuracy in the individual patient. Clinical Trials No. NCT01538290.